Impact of COVID-19 Pandemic on the Use of Antidepressant and Antianxiety Pharmaceuticals as Well as Sick Leave in Poland

Int J Environ Res Public Health. 2022 Feb 14;19(4):2135. doi: 10.3390/ijerph19042135.

Abstract

The COVID-19 pandemic caused a major upheaval to the lives of people and placed a strain on societal mental health. The aim of this research is to estimate the impact of the pandemic on the mental condition of the Polish population measured through the consumption of relevant medication and medical leave of absence from the workplace.

Methods: We analyzed national-level data on the consumption of pharmaceuticals used in clinical practice in Poland in the treatment of depression and anxiety alongside medical absence in the workplace using the Interrupted Time Series model to estimate the significance of the pandemic.

Results: We found no significant change regarding the consumption of pharmaceuticals with the development of the pandemic. Conversely, medical leaves of absence for psychiatric reasons increased significantly with the onset of COVID-19. The influence was strongest in the diagnosis of anxiety or reaction to severe stress and weakest in recurrent depression.

Conclusion: The pandemic had a significant influence on the ability to work for psychiatric patients in Poland but did not change pharmaceutical use. Physicians should consider the mental health of patients impacted by the anti-epidemic measures. Further study is needed to fully understand the long-term impact of the pandemic on mental health in Poland.

Keywords: COVID-19; Poland; antianxiety; antidepressants; anxiety; depression; mental health; pharmaceuticals; sick leave.

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Anxiety / drug therapy
  • Anxiety / epidemiology
  • Anxiety / psychology
  • COVID-19 Drug Treatment*
  • COVID-19* / epidemiology
  • Depression / drug therapy
  • Depression / epidemiology
  • Depression / psychology
  • Humans
  • Pandemics
  • Pharmaceutical Preparations*
  • Poland / epidemiology
  • SARS-CoV-2
  • Sick Leave

Substances

  • Antidepressive Agents
  • Pharmaceutical Preparations